[1] Köhler, G. & Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495–497 (1975).
[2] Sanger, F., Nicklen, S. & Coulson, A. R. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A 74, 5463–5467 (1977).
[3] Baker, M. Antibody anarchy: A call to order. Nature 527, 545–551 (2015).
[4] Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015).
[5] Bradbury, A. M. & Plückthun, A. Antibodies: validate recombinants once. Nature 520, 295 (2015).
[6] Bradbury, A. & Plückthun, A. Reproducibility: Standardize antibodies used in research. Nature 518, 27–29 (2015).
[7] Freedman, L. P. & Gibson, M. C. The impact of preclinical irreproducibility on drug development. Clin. Pharmacol. Ther. 97, 16–18 (2015).
[8] Freedman, L. P., Cockburn, I. M. & Simcoe, T. S. The Economics of Reproducibility in Preclinical Research. PLoS Biol. 13, e1002165 (2015).
[9] Bradbury, A. R. M., Dübel, S., Knappik, A. & Plückthun, A. Animal- versus in vitro-derived antibodies: avoiding the extremes. MAbs 13, 1950265 (2021).
[10] Bradbury, A. R. M. et al. When monoclonal antibodies are not monospecific: Hybridomas frequently express additional functional variable regions. MAbs 10, 539–546 (2018).